

## Erratum to: Cost Effectiveness of Paricalcitol Versus Cinacalcet with Low-Dose Vitamin D for Management of Secondary Hyperparathyroidism in Haemodialysis Patients in the USA

Amit Sharma · Thomas S. Marshall ·  
Samina S. Khan · Beverly Johns

Published online: 3 January 2014  
© Springer International Publishing Switzerland 2013

### Erratum to: Clin Drug Investig DOI 10.1007/s40261-013-0151-4

A Published-Ahead-of-Print version of this article was made available online at <http://link.springer.com/article/10.1007/s40261-013-0151-4> on 09 November 2013. Errors were subsequently identified in that version of the article, and the following corrections should be noted:

#### Section 3.1, line 5, which previously read:

“As shown in Table 2, among US patients, 29 (56.9 %) in the paricalcitol group and 16 (34.0 %) in the cinacalcet group reached this endpoint (a difference of 23 %,  $p = 0.0235$ ).”

Should read:

“As shown in Table 3, among US patients, 29 (56.9 %) in the paricalcitol group and 16 (34.0 %) in the cinacalcet group reached this endpoint (a difference of 23 %,  $p = 0.0235$ ).”

---

The online version of the original article can be found under doi:[10.1007/s40261-013-0151-4](https://doi.org/10.1007/s40261-013-0151-4).

---

A. Sharma  
Nephrian Inc., 870 Paseo Santa Cruz, Thousand Oaks,  
CA 91320-6779, USA  
e-mail: sharmaaxs@gmail.com

T. S. Marshall (✉) · S. S. Khan · B. Johns  
AbbVie, Inc., 1 North Waukegan Road,  
North Chicago, IL 60064, USA  
e-mail: t.marshall@abbvie.com

S. S. Khan  
e-mail: samina.khan@abbvie.com

B. Johns  
e-mail: beverly.a.johns@abbvie.com

#### Section 3.3, first paragraph, line 8, which previously read:

“Table 3 also shows the difference between the paricalcitol and cinacalcet groups in the proportions of patients who responded, based on each endpoint included (based on data in Table 2).”

Should read:

“Table 4 also shows the difference between the paricalcitol and cinacalcet groups in the proportions of patients who responded, based on each endpoint included (based on data in Table 3).”

#### Section 3.3, third paragraph, line 1, which previously read:

“Figure 1 is a scatterplot of all 1,000 bootstrap replicates, with the  $x$ -axis representing the incremental cost and the  $y$ -axis representing the incremental effectiveness of the paricalcitol-based regimen compared with the cinacalcet-based regimen, where effectiveness is the proportion of subjects reaching an iPTH level of 150–300 pg/mL.”

Should read:

“Figure 1 is a scatterplot of all 1,000 bootstrap replicates, with the  $x$ -axis representing the incremental effectiveness and the  $y$ -axis representing the incremental cost of the paricalcitol-based regimen compared with the cinacalcet-based regimen, where effectiveness is the proportion of subjects reaching an iPTH level of 150–300 pg/mL.”